We've updated our Privacy Policy to make it clearer how we use your personal data. We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement

Nastech Announces Multi-Compound Agreement with Novo Nordisk

News  
Published: March 20, 2006
 
Listen with
Speechify
0:00
Register for free to listen to this article
Thank you. Listen to this article using the player above. ✖

Want to listen to this article for FREE?

Complete the form below to unlock access to ALL audio articles.

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy
Read time: Less than a minute

Nastech Pharmaceutical Company Inc. has announced that it has entered into a multi-compound, feasibility study agreement with Novo Nordisk A/S with respect to certain Novo Nordisk therapeutic compounds.

"Nastech is honored to be working with Novo Nordisk, a world-leader in therapies for metabolic disease," said Steven C. Quay, M.D., Ph.D., Chairman, President and CEO of Nastech.

"Novo Nordisk is known for its ethical standards and has participated in many innovative advances in medical practice."

Advertisement
Advertisement
Advertisement
Decoratvive background images
Never miss a story
with the Breaking Science News daily newsletter